Theriva Biologics Faces Delay in Warrant Approval Meeting

Theriva Biologics ( (TOVX) ) has issued an announcement.

On February 11, 2026, Theriva Biologics, Inc. attempted to hold a Special Meeting of Stockholders but was unable to convene it because there were not enough shares present or represented by proxy to constitute a quorum. The company will now call a new stockholder meeting to seek approval of its warrant exercise and adjournment proposals and will send fresh proxy materials to investors ahead of that meeting.

The Special Meeting had been called to obtain stockholder approval for the potential issuance of up to 16,184,560 shares of common stock upon exercise of new warrants issued under an October 16, 2025 inducement agreement with institutional investors. Because the meeting could not be convened, Theriva must, unless the investors waive this requirement, continue calling additional stockholder meetings every 60 days to seek this approval until it is obtained or the new warrants are no longer outstanding, adding ongoing procedural and timing uncertainty for stakeholders.

The most recent analyst rating on (TOVX) stock is a Hold with a $0.17 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.

Spark’s Take on TOVX Stock

According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.

The score is primarily constrained by weak financial performance (pre-revenue losses, material cash burn, and a shrinking equity base that raises financing/dilution risk). Technical signals are mixed-to-weak with negative MACD and price below key longer-term averages. Offsetting these risks, corporate events are constructive, highlighted by positive Phase 2b data and EMA support for a pivotal Phase 3 trial.

To see Spark’s full report on TOVX stock, click here.

More about Theriva Biologics

Theriva Biologics, Inc. is a biotechnology company focused on developing therapeutic products, with its capital structure supported by common stock and warrant financing arrangements involving institutional investors. The company relies on stockholder approvals to authorize the issuance of additional shares tied to these warrant agreements, which can influence its funding flexibility and shareholder dilution.

Average Trading Volume: 5,349,177

Technical Sentiment Signal: Strong Sell

Current Market Cap: $6.92M

For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.